Clinical value of offering multiple chemotherapy lines to a luminal-like metastatic breast cancer: A case report with eribulin.

INTRODUCTION: The achievement of complete response with chemotherapy after multiple treatment lines in metastatic breast cancer and the chemosensitivity in a luminal-like breast cancer are two important issues as it is often asked whether there is a potential limit to the number of therapeutic lines offered and what clinical value they may have. In this setting, eribulin mesylate is a chemotherapy option available. Several randomized and observational studies demonstrated eribulin's meaningful improvement on prolongation of survival, chronicling the disease and preventing the onset of new metastases, although the rate of complete responses is rather limited. CASE DESCRIPTION: We report the five-year history of a luminal A breast cancer, stage IV at diagnosis, metastasized to bone and brain. After undergoing four chemotherapy lines and several radiotherapy sessions with partial response as the best response on bone and with a complete response on brain, our patient finally achieved a metabolic complete response also on bone after about a year of fifth-line treatment with eribulin. Currently the patient is in close clinical and radiological follow-up. CONCLUSIONS: This case report aims to emphasize the clinical value of a chronic chemotherapy treatment also in heavily pretreated and luminal-like metastatic breast cancer, supporting eribulin as a good choice to consider.

[Risk of firearms abuse: a review of the literature and a proposal of medical procedures for prevention]. / Rischio di abuso di armi da fuoco: rassegna della letteratura e proposte di procedure mediche di prevenzione.

Aim of this study is a critical review of the procedures of medical and psychological evaluation for people requiring firearms certificates, on the base of evidences from the scientific literature and the current knowledge about mental processes.

18F-fluorodeoxyglucose-positron emission tomography in the characterization of suspected rhabdoid renal tumor recurrence: a case report.

Rhabdoid tumor is a rare, aggressive, and undifferentiated cancer, that can be localized in the central nervous system, in the thorax or in the kidney. 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) is a noninvasive technique in cancer patients' management. Its role in the diagnosis and staging of rhabdoid renal tumor is not known at all. We report the case of a child with suspected recurrence of rhabdoid renal tumor studied with FDG-PET/computed tomography. A 4-year-old male previously treated for a rhabdoid tumor of the left kidney, underwent PET scan to differentiate local recurrence from postsurgical fibrosis. FDG-PET study showed the presence of intense, multiple, and inhomogeneous tracer uptakes in the left renal fossa (ie, the site of suspected computed tomography recurrence), with the involvement of the adjacent abdominal wall. Further pathologic uptakes were evidenced in the para-aortic, celiac, mesenteric areas, and at the hepatic hilum. Therefore, PET scan allowed a complete disease staging, evidencing unexpected local and distant disease extension. Thus, FDG-PET study could be considered in the evaluation of patients with renal rhabdoid tumor, at least when disease recurrence is suspected.